Company intelligence / Profile preview
META Pharmaceuticals Inc.
Shenzhen, Guangdong, China
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has identified a series of new druggable targets with first-in-class potential and developed a pipeline with three first-in-class small molecule inhibitors, one of which is expected to file for IND in both the US and China as early as 2024.
- Therapeutic areas
- OncologyMetabolic DisordersImmunologyOther
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
XtalPi Inc. (Crystal Jade)
Beyond the preview
Go deeper on META Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on META Pharmaceuticals Inc..